Remedy Meds vs ShedRx (2026): prices, structure, verdict

On tirzepatide, ShedRx↗ is cheaper: $289 versus $399 a month all-in — a $110 monthly gap, $1,320 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, ShedRx is cheaper: $249 versus $299 a month all-in — a $50 monthly gap, $600 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Remedy Meds: the record, condensed

Remedy Meds’s tirzepatide program bills $399 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Remedy Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #15 of 17 verified programs, with the floor $184/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

On semaglutide, the number that matters at Remedy Meds is $299 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Remedy Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #19 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

ShedRx: the record, condensed

Start with the load-bearing figure: $289 a month, all-in, is what ShedRx charges for tirzepatide at the 10 mg basis. Note the shape: $199 is the number in the marketing, $289 is the number at maintenance. The $90 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #5 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

ShedRx’s semaglutide program bills $249 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Note the shape: $175 is the number in the marketing, $249 is the number at maintenance. The $74 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $249 is the whole subscription, which makes ShedRx unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #13 of 20 in the verified semaglutide index — $116/month above the floor (Oak Longevity, $133) — and sits $100 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,988.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: ShedRx at $289, Remedy Meds at $399 — a $110 monthly spread that compounds to $1,320 over a maintenance year and $2,640 over two.

Structure sharpens the gap: Remedy Meds’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while ShedRx’s is not — so Remedy Meds’s number is a ceiling and ShedRx’s advertised entry ($199) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $249 (ShedRx) against $299 (Remedy Meds). $50 a month sounds survivable; $600 a year is a decision.

Structure sharpens the gap: Remedy Meds’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while ShedRx’s is not — so Remedy Meds’s number is a ceiling and ShedRx’s advertised entry ($175) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

A way to feel the $110 monthly gap: over a year it funds 4.6 extra months at ShedRx’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $2,640, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Remedy Meds $399/mo month-to-month against ShedRx $289/mo month-to-month. The order holds: ShedRx leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Remedy Meds $1,197 monthly; ShedRx $867 monthly — best path favors ShedRx by $330. 6 months: Remedy Meds $2,394 monthly; ShedRx $1,734 monthly — best path favors ShedRx by $660. 12 months: Remedy Meds $4,788 monthly; ShedRx $3,468 monthly — best path favors ShedRx by $1,320. 24 months: Remedy Meds $9,576 monthly; ShedRx $6,936 monthly — best path favors ShedRx by $2,640.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Remedy Meds $897 vs ShedRx $747 — $150 to ShedRx. 6 mo: Remedy Meds $1,794 vs ShedRx $1,494 — $300 to ShedRx. 12 mo: Remedy Meds $3,588 vs ShedRx $2,988 — $600 to ShedRx. 24 mo: Remedy Meds $7,176 vs ShedRx $5,976 — $1,200 to ShedRx.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Remedy Meds publishes “not published”; ShedRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Remedy Meds — unknown; not published. ShedRx — none month-to-month; 72-hour notice before the next billing cycle.

Evidence: Remedy Meds third-party reported (captured 2026-08-05); ShedRx source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #15 and #5 of 17: between them lie 9 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #19 and #13 of 20: between them lie 5 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Remedy Meds and ShedRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Remedy Meds: not published; ShedRx: 72-hour notice before the next billing cycle) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings